Compare Ingersoll Rand (IR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ingersoll Rand vs Tango Therapeutics Inc. — how do they compare? Ingersoll Rand trades at $77.95 (market cap $30.24B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Ingersoll Rand is far larger — about 8.1× Tango Therapeutics Inc.'s market cap, and Ingersoll Rand pays a 0.1% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 9 Days and Tango Therapeutics Inc. for 0 Days on average.
| IR | TNGX | |
|---|---|---|
Market Cap | $30.24B | $3.74B |
Volume | 2,589,571 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $98.76 | $32.90 |
52-Week Low | $68.54 | $7.50 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $33.90B | $2.76B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ingersoll Rand (IR) trades at $78.95, down 0.18% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $0.86 versus $0.827 expected, marking three consecutive quarterly beats. Revenue guidance was raised to 4.5%-6.5% for 2026, with improving demand across business cycles. Analyst consensus is bullish with a $90.60 price target, representing 15% upside potential from current levels.
The outlook remains positive with accelerating long-cycle orders and strategic acquisitions expanding capabilities. Key risks include margin compression and elevated P/E ratio of 32.62. Institutional ownership increased with HSBC boosting its position by 12.9% in Q2 2026. The stock offers growth potential but requires monitoring of profitability trends and valuation sustainability.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
